Last reviewed · How we verify
TOL2506
TOL2506 is a long-acting leuprolide acetate formulation designed to suppress luteinizing hormone and testosterone levels.
TOL2506 is a long-acting leuprolide acetate formulation designed to suppress luteinizing hormone and testosterone levels. Used for Advanced prostate cancer, Endometriosis.
At a glance
| Generic name | TOL2506 |
|---|---|
| Sponsor | Tolmar Inc. |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TOL2506 is a sustained-release depot formulation of leuprolide, a GnRH agonist that initially stimulates and then suppresses gonadotropin secretion, leading to sustained suppression of testosterone production. This mechanism is utilized in the treatment of hormone-dependent conditions such as prostate cancer and endometriosis, where prolonged testosterone suppression is therapeutically beneficial.
Approved indications
- Advanced prostate cancer
- Endometriosis
Common side effects
- Hot flashes
- Injection site reaction
- Testosterone surge (initial)
- Decreased libido
Key clinical trials
- Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (PHASE3)
- Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TOL2506 CI brief — competitive landscape report
- TOL2506 updates RSS · CI watch RSS
- Tolmar Inc. portfolio CI